For Healthcare Professionals
Taffix is formulated with ingredients designated by the US Food and Drug Administration (FDA) as Generally Recognized as Safe (GRAS) and approved as inactive ingredients for nasal use. These ingredients are commonly used as excipients in pharmaceutical preparations, particularly in eye preparations and nasal sprays.
Taffix was developed based on established scientific principles and knowledge of the impact of pH on viral survival, combined with precedence for use of gel-based muco-adhesives in products intended for intranasal administration to coat the nasal mucosa and block passage of foreign bodies across the mucosal membrane.3,5
Low pH (3,5) nasal sprays can inactivate the influenza virus.8
In another in vitro study9, Taffix significantly reduced the Influenza A (H1N1) virus infection in Madin-Darby Canine Kidney (MDCK) cells, with anti-viral activity measured within 5 minutes of exposure of the virus to Taffix at conditions mimicking the human nasal cavity. Taffix-treated MDCK cells exposed to the H1N1 virus demonstrated 89 % averaged cell viability in comparison to 26 % averaged viability of cells infected with the H1N1 virus and not pre-treated with Taffix. Furthermore, Taffix was shown not to be toxic to MDCK cells.